menu
    • menu
    [{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Radiant Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Radiant Biotherapeutics

    Menu

    Radiant Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Radiant Bio Raises $35M To Advance Multabody™ Therapeutic Platform

                            Details : This financing will enable the next stage in Radiant’s growth and move the company toward the clinic, Multabody platform against therapeutic targets that cannot be treated with traditional antibodies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 11, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV

                            Details : The funding aims to support Radiant to develop the next generation of HIV biologics based on Radiant’s Multabody platform, which can destroy latent stores of the HIV virus, along with its ability to eliminate circulating viral particles.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radiant Biotherapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Amplitude Ventures

                            Deal Size : $8.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships

                            Details : The financing will advance and validate Radiant's Multabody platform among several oncology programs. Radiant’s Multabody platform exploits avidity - stronger binding power - coupled with multi-specificity to deliver highly efficacious antibodies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 25, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Amplitude Ventures

                            Deal Size : $8.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth